Glen Eagle Resources Announces Appointment of New Director to the Board

(TheNewswire)

Glen Eagle Resources Inc. (the " Corporation ") (TSXV:GER) is pleased to announce that Armando Farhate has been appointed as Director of the Corporation, as part of its restructuring process

Armando Farhate, a Brazilian citizen, has more than 35 years of industry experience with the last twelve years being focused in the mining sector. He has occupied C-Level and Upper Management positions in mining companies in Brazil, Canada, Namibia and Botswana, and is currently Director of three other Canadian mining and exploration companies. He brings extensive expertise in all areas of this industry segment, with special focus on operations, Sales & Marketing, Engineering and Mineral Resource Development.

Mr. Farhate holds a Mechanical Engineering degree, an MBA and is a Certified Board Member by IBGC (Brazil). He carried out several mandates in 33 different countries and speaks 7 languages fluently. He's currently COO & Head of Graphite Market and Sales at Gratomic Inc, a Canadian public company focused on developing graphite assets aiming to supply the fast-developing Electric Vehicle (EV) sector with a critical mineral for the batteries.

"Armando is a team player, with whom I have had the privilege to collaborate with for many years. He will bring Glen Eagle crucial expert advises, not only to continue developing its gold assets in Latin America, but also to help assess opportunities to transition into new critical minerals for serving the booming EV industry" noted Karl Trudeau, President and CEO of the Corporation.

ABOUT GLEN EAGLE RESOURCES INC.

Glen Eagle Resources Inc. is a small producer and an exploration company of precious metals in Canada and the Central America area.

For more information, please contact:

Karl Trudeau
President
1-819-440-8495

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties,. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Corporation, including the timing and nature of all regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

Copyright (c) 2023 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×